<DOC>
	<DOCNO>NCT01807221</DOCNO>
	<brief_summary>To assess new drug , BAY94-8862 , give orally different dos , evaluate whether safe help well-being patient worsen chronic heart failure either type II diabetes without chronic kidney disease kidney disease alone . These treatment dos compare eplerenone , another market drug approve treat heart failure .</brief_summary>
	<brief_title>Phase IIb Safety Efficacy Study Different Oral Doses BAY94-8862 Subjects With Worsening Chronic Heart Failure Left Ventricular Systolic Dysfunction Either Type 2 Diabetes Mellitus With Without Chronic Kidney Disease Chronic Kidney Disease Alone</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Ventricular Dysfunction , Left</mesh_term>
	<mesh_term>Eplerenone</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>Men woman age 18 year old . The low age limit may higher legally require participate country Women childbearing potential include study pregnancy test negative agree use adequate contraception sexually active Subjects worsen chronic heart failure require emergency presentation hospital treatment intravenous diuretic hospital Subjects clinical diagnosis chronic heart failure ( CHF ) either ischemic non ischemic , New York Heart Association ( NYHA ) functional class IIIV Subjects type 2 diabetes mellitus / Subjects 30 mL/min/1.73m2 &lt; /= eGFR &lt; /= 60 mL/min/1.73m2 ( MDRD , Modification Diet Renal Disease Study Group ) screen Left ventricular ejection fraction ( LVEF ) &lt; /= 40 % Blood potassium &lt; /= 5.0 mmol/L screen Systolic blood pressure &gt; /= 90 mmHg without sign symptom hypotension screen visit Acute denovo heart failure acute inflammatory heart disease , e.g . acute myocarditis Acute coronary syndrome ( ACS ) last 30 day prior screen Cardiogenic shock Valvular heart disease require surgical intervention course study Stroke transient ischemic cerebral attack last 3 month prior screen visit Concomitant treatment mineralocorticoid receptor antagonist ( MRA ) , renin inhibitor , potassiumsparing diuretic</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Heart Decompensation</keyword>
</DOC>